Optimal stroke prevention using oral anticoagulant (OAC) therapy is essential for the management of patients with atrial fibrillation (AF) who are at increased risk of stroke, but decision making on thromboprophylaxis requires evaluation of individual patient's thromboembolic and bleeding risks.
1 Several risk assessment tools have been developed to streamline the evaluation of patients with AF but navigating through the labyrinth of options may be confusing for clinicians. Not surprisingly, the CHADS 2 and CHA 2 DS 2 -VASc scores were the most commonly evaluated stroke risk assessment tools (29 and 24 studies, respectively). Overall, the CHADS 2 , CHA 2 DS 2 -VASc and ABC-stroke scores had the best evidence for prediction ability for stroke-however, notwithstanding the heterogeneity among studies included in the metaanalyses, the CHADS 2 , CHA 2 DS 2 -VASc, Framingham and ABC-stroke scores all had a modest prediction ability for thromboembolic events, with c-statistic values ranging from 0.63 (Framingham) to 0.69 (continuous CHADS 2 score).
3 This is in line with previous meta-analyses [5] [6] [7] [8] showing broadly similar performance of various clinical risk factor-based stroke scores (including the CHA 2 DS 2 -VASc) in prediction of thromboembolic events. However, the difference of the CHA 2 DS 2 -VASc in comparison to other stroke scores is its relative accuracy in identifying AF patients at truly low risk of stroke (i.e. CHA 2 DS 2 -VASc of 0 in men, or 1 in women) who do not need any anti-thrombotic therapy.
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Recognizing that all clinical scores only have modest predictive value for high-risk patients that sustain events and that current risk scores are designed to be simple and reductionist, the use of a simplified, clinical risk factor-based approach to the management of AF-related stroke risk has been acknowledged by recent international AF guidelines.
1,11 The default should be to 'offer stroke prevention, unless the patient is "low risk"'. A simple message is needed, as guideline-adherent treatment has been associated with improved outcomes in multiple AF cohorts.
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The presence of even a single CHA 2 DS 2 -VASc risk factor is associated with an excess in stroke and mortality, 17, 18 and OAC use is associated with positive net clinical benefit in comparison to aspirin (which is harmful) or no therapy. ; however, ignoring female sex (i.e. using the CHA 2 DS 2 -VA score, without 'Sc'
23
) could under-estimate stroke risk in females with AF.
24
As mentioned, clinical risk factor-based scores generally have a modest prediction ability for the outcome event of interest. Adding various biomarkers ('biological markers') to clinical scores-that is, blood biomarkers (e.g. brain natriuretic peptide, cardiac troponin, creatinine, etc.), cardiac or cerebral imaging (echocardiographic, magnetic resonance, etc.) or electrocardiographic indices in sinus rhythm (e.g., the P wave axis 25 )-improve the score's prediction ability, at least statistically, but such complexity may be impractical or unfeasible outside a highly structured setting. 
Bleeding Risk Assessment
Bleeding risk assessment is a sensitive part of risk evaluation in AF patients that is sometimes misinterpreted or even abused. 28 All international AF guidelines recommend bleeding risk assessment but beyond listing the bleeding risk factors, practical guidance on clinical decision making on Invited Editorial Focus 2015
OAC use in high-risk AF patients at increased risk of bleeding is less well specified.
1
In their systematic review and evidence appraisal, Borre et al 3 also explored 38 studies that reported on bleeding risk in AF patients. Overall, they found moderate strength of evidence on increased bleeding risk in AF patients with chronic kidney disease, and that the HAS-BLED score provided the best prediction of bleeding events among the investigated bleeding risk assessment tools. Indeed, the HAS-BLED score has been extensively validated in various setting, including AF patients on OAC (either vitamin K antagonists [VKA] or non-VKA OACs), aspirin or no antithrombotic therapy, with respect to various bleeding outcomes (i.e. major bleeding or intracranial haemorrhage).
28
Bleeding risk assessment using the HAS-BLED score is not meant to preclude the use of OAC, but to identify high-risk patients in whom modifiable bleeding risk factors such as uncontrolled hypertension (H), labile international normalized ratios in patient taking VKAs (L), concomitant use of non-steroidal anti-inflammatory drugs, anti-platelet drugs or excessive alcohol consumption (D) can be addressed or modified, and who need clinical follow-up earlier rather than later (e.g. 4 weeks rather than 4-6 months). Importantly, using a formal bleeding risk assessment tool (i.e. the HAS-BLED score) had significantly better predictive value for bleeding risk assessment compared with the approach based only on modifiable bleeding risk factors.
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The Dynamic Nature of Stroke and Bleeding Risk Many studies of risk factors and biomarkers have investigated something at study entry ('baseline') and ascertained outcomes many years later (sometimes 5 or 10 years). The patient's clinical risk profile changes over time and this change has been shown to have better prediction ability for the respective risk than simply relying on the baseline score values. 32, 33 Hence, neither thromboembolic nor bleeding risks are static and must be re-assessed regularly. This is part of a comprehensive and holistic approach to the management of patients with AF 34 (see ►Fig. 1).
